Abstract
Anti-melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis is known to associate with rapidly progressive interstitial lung disease and cutaneous ulcer. The prognosis is often poor even with intensive treatment, with data from the local cohort showing 37.9% mortality [1]. Here, we report a case of refractory anti-MDA5 antibody-associated dermatomyositis that occurs shortly after COVID-19 infection and was managed using a combination of treatments that target different aspects of disease pathology.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
